Targeting MDM4 Splicing in Cancers

被引:21
|
作者
Bardot, Boris [1 ]
Toledo, Franck [1 ]
机构
[1] PSL Res Univ, Sorbonne Univ, UPMC Univ Paris 06,Inst Curie,Ctr Rech, CNRS UMR 3244,Genet Suppress Tumorale,Equipe Lab, 26 Rue Ulm, F-75248 Paris 05, France
关键词
MDM4; MDM2; p53; alternative splicing; isoform; PRE-MESSENGER-RNA; THERAPEUTIC TARGET; P53; INHIBITION; BCL-X; DOMAIN; MICE; EXPRESSION; REVEALS; CELLS; GENE;
D O I
10.3390/genes8020082
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
MDM4, an essential negative regulator of the P53 tumor suppressor, is frequently overexpressed in cancer cells that harbor a wild-type P53. By a mechanism based on alternative splicing, the MDM4 gene generates two mutually exclusive isoforms: MDM4-FL, which encodes the full-length MDM4 protein, and a shorter splice variant called MDM4-S. Previous results suggested that the MDM4-S isoform could be an important driver of tumor development. In this short review, we discuss a recent set of data indicating that MDM4-S is more likely a passenger isoform during tumorigenesis and that targeting MDM4 splicing to prevent MDM4-FL protein expression appears as a promising strategy to reactivate p53 in cancer cells. The benefits and risks associated with this strategy are also discussed.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] MDM4 alternative splicing and implication in MDM4 targeted cancer therapies
    Wu, Jin
    Lu, Guanting
    Wang, Xinjiang
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (12): : 5864 - 5880
  • [2] MDM2 and MDM4 splicing: an integral part of the cancer spliceome
    Jeyaraj, Selvi C.
    O'Brien, Dennis M.
    Chandler, Dawn S.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 : 2647 - 2656
  • [3] A defective splicing machinery promotes senescence through MDM4 alternative splicing
    Deschenes, Mathieu
    Durand, Mathieu
    Olivier, Marc-Alexandre
    Pellerin-Viger, Alicia
    Rodier, Francis
    Chabot, Benoit
    AGING CELL, 2024, 23 (11)
  • [4] RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4
    Weinstein, Hannah N. W.
    Hu, Kevin
    Fish, Lisa
    Chen, Yih-An
    Allegakoen, Paul
    Pham, Julia H.
    Hui, Keliana S. F.
    Chang, Chih-Hao
    Tutar, Meltem
    Benitez-Rivera, Lorena
    Baco, Maria B.
    Song, Hanbing
    Giacomelli, Andrew O.
    Vazquez, Francisca
    Ghandi, Mahmoud
    Goodarzi, Hani
    Huang, Franklin W.
    CELL REPORTS, 2024, 43 (08):
  • [5] Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy
    Li, Qin
    Lozano, Guillermina
    CLINICAL CANCER RESEARCH, 2013, 19 (01) : 34 - 41
  • [6] RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4
    Weinstein, Hannah N.
    Hu, Kevin
    Fish, Lisa
    Chen, Yih-An
    Allegakoen, Paul
    Hui, Keliana S.
    Pham, Julia H.
    Baco, Maria B.
    Song, Hanbing
    Giacomelli, Andrew O.
    Vazquez, Francisca
    Ghandi, Mahmoud
    Goodarzi, Hani
    Huang, Franklin W.
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Regulation of MDM4
    Markey, Michael P.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 1144 - 1156
  • [8] Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
    Cao, Lei
    Fan, Lei
    Xu, Wei
    Li, Jian-Yong
    CURRENT CANCER DRUG TARGETS, 2015, 15 (09) : 769 - 780
  • [9] Targeting MDM4 in neuroblastoma to reactivate p53 signaling
    Woodfield, Sarah E.
    Patel, Roma H.
    Ibarra, Aryana M.
    Chen, Zhenghu
    Vasudevan, Sanjeev A.
    CANCER RESEARCH, 2018, 78 (19)
  • [10] Targeting MDM4 to reactivate p53 signaling in neuroblastoma
    Chen, Zhenghu
    Woodfield, Sarah E.
    Patel, Roma H.
    Ibarra, Aryana M.
    Vasudevan, Sanjeev A.
    CANCER RESEARCH, 2019, 79 (13)